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Abstract
Among various machineries occurring in the experimental neuropathic pain model, there exists the
loss of pain transmission through C-fiber neurons as well as the hypersensitivity through A-fibers.
The current study reveals that molecular machineries underlying the latter hypersensitivity are
derived from the events through LPA1 receptor and its downstream RhoA-activation following
peripheral nerve injury. The loss of C-fiber responses, which are mediated by spinal substance P
(SP) pain transmission was observed with the nociceptive flexor responses by intraplantar injection
of SP in nerve-injured mice. The immunohistochemistry revealed that SP signal in the dorsal horn
was markedly reduced in such mice. All these changes were completely abolished in LPA1
-/- mice
or by the pretreatment with BoNT/C3, a RhoA inhibitor. In addition, the loss of C-fiber responses
and the down-regulation of spinal SP signal induced by single intrathecal LPA injection were also
abolished in such treatments. All these results suggest that the loss of pain transmission through
polymodal C-fiber neurons is also mediated by the LPA1 activation following nerve injury.
Findings
Injury to peripheral nerves cause rearrangement of synap-
tic contacts, wind up, central sensitization, long-term
potentiation and loss of inhibitory neuron of the spinal
dorsal horn [1-7]. Retraction and the following lack of sig-
nals from polymodal C-fiber terminals to dendritic targets
in lamina II of the dorsal spinal cord, and sprouting of
mechanoreceptor Aβ-fibers (which terminate in laminae
III-V) to form new connections with the vacated dendrites
of the second order nociceptive neurons in lamina II, are
suspected to be partially responsible for the abnormal
pain sensations, or allodynia associated with peripheral
nerve damage [2,5,8]. The mechanisms behind these
rerouting processes may be driven by specific factors
mediating neurite retraction.
The bioactive lipid mediator, lysophosphatidic acid
(LPA), which is generated after nerve injury and impli-
cated in pathological pain, signals through the LPA1 recep-
tor to activate G12/13  and the small GTPase signaling
molecule RhoA, may serve as a candidate signaling-mole-
cule for inducing the retraction of polymodal C-fibers in
vivo as it has been found to induce neurite retraction in
vitro [9-15]. Recently, we reported that the LPA1 receptor is
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necessary to initiate neuropathic pain, neuronal demyeli-
nation and up-regulation of pain-related proteins follow-
ing nerve injury [16]. In addition, intrathecal (i.t.)
injection of LPA mimics nerve injury-induced behavioral,
morphological and biochemical changes[16]. Inhibition
of the RhoA downstream pathway of LPA1 receptor activa-
tion has shown that this pathway is essential for both
nerve injury- and LPA-induced neuropathic pain.
In the present study, we sought to determine, whether
activation of LPA1 receptor and the downstream RhoA
pathway are required for abrogation of polymodal C-fiber
signaling following nerve injury. Decreased polymodal C-
fiber signaling was evaluated by spinal SP immunohistol-
ogy as well as nociceptive responses through SP-contain-
ing polymodal C-fibers following nerve injury.
Furthermore, we investigated whether i.t injection of LPA
would mimic the spinal SP and nociceptive profile of
mice subjected to nerve injury.
Male Std-ddY mice, and mice lacking the lpa1 gene (LPA1
-
/-), and its wild typed mice weighing 20–22 g maintained
at 21 ± 2°C with food and water ad libitum were used
throughout the experiments. All procedures were
approved by the Nagasaki University Animal Care Com-
mittee and complied with the recommendations of the
IASP [17]. Partial ligation of the sciatic nerve was per-
formed as described previously [16,18]. Experiments were
carried out at 7 days. Algogenic-induced paw-flexor
response (APF) tests were performed as described previ-
ously [6,19]. LPA (Avanti Polar-Lipids, Alabaster, AL) was
dissolved in A-CSF (NaCl 125 mM, KCl 3.8 mM, CaCl2 2.0
mM, MgCl2 1.0 mM, KH2PO4 1.2 mM, NaHCO3 26 mM,
Glucose 10 mM), and was injected intrathecally (i.t.)
between lumbar 5 and 6 regions. Most of the experiments
were conducted 24 h following injection LPA (1 nmol in
5 μl). BoNT/C3 was a kind gift from Dr. Shuji Kozaki.
BoNT/C3 was delivered intrathecally (10 pg in 5 μl) 1 hr
prior to nerve-injury or LPA-treatment. All behavioral
experiments were carried out by investigators blinded to
the drug-treatment.
For histological examinations, mice were deeply anesthe-
tized and perfused with potassium-free phosphate-buff-
ered saline (K+  free PBS, pH7.4), followed by 4%
paraformaldehyde. The spinal cord was removed, post-
fixed for 3 hours and cryoprotected overnight in 25%
sucrose and finally fast frozen in cryoembedding com-
pound. The spinal cord was cut at 30 μm and incubated
with 50% methanol for 10 min, and then 100% methanol
for 10 min. The sections were washed, incubated with
blocking buffer containing 2% BSA for 60 min, and then
reacted overnight at 4°C with goat anti SP antibodies
(1:500) in blocking buffer. After washing, the sections
were placed in Alexa488-conjugated secondary antibodies
(1:300) for 120 min at RT. After washing, spinal cord sec-
tions were mounted on glass slides, treated with Perma-
Fluor (Thermo Shandon, Pittsburgh, PA), protected with
cover slips and examined by fluorescence microscopy
(Keyence, Japan). Changes in spinal cord SP immunoreac-
tivity were analyzed with the Image J software on digital
images with a grey scale from 0 to 255. The SP signal was
determined as the total signal in the superficial dorsal
horn after background subtraction. Statistical analyses
were performed using Student's t-test. Significance was set
to p < 0.05. All results are expressed as means ± S.E.M.
After the confirmation that mice showed no spontaneous
moving approximately 20 min after the cannulation, they
were intraplantarly (i.pl.) given with SP (Peptide Institute,
Osaka, Japan) to see changes in nociceptive flexor
responses by nerve injury or LPA-treatment. SP induced a
dose-dependent nociceptive flexor response from 0.01 to
1 pmol in sham-operated mice, but not in injured mice
(Table 1) as previously reported in Std-ddY mice[6]. How-
ever, the loss of SP-sensitivity in injured mice was reversed
in LPA1
-/-  mice (Table 1). Similar reversal was also
observed in mice i.t. pretreated with 10 pg of C3-typed
botulinum toxin (BoNT/C3), a selective inhibitor of ADP-
ribosylation of RhoA (Table 1). The loss of SP-sensitivity
was also observed when mice were treated with LPA (1
nmol, i.t.) 24 hr prior to the APF test (Table 1). Similarly,
the loss of function was also reversed in LPA1-/- mice or in
mice pretreated with BoNT/C3 (Table 1).
As shown in Fig. 1A, a marked decrease in SP immunore-
activity in the ipsilateral superficial dorsal horn was
observed at day 7 in nerve injured mice compared to sham
operated controls, as previously reported[20]. The SP
immunoreactivity in the lamina I and II of spinal dorsal
horn was significantly reduced to approximately 50% of
control by the nerve injury (Fig. 1C). The injury-induced
reduction was completely prevented in LPA1-/- mice and
in mice pretreated with BoNT/C3 (10 pg, i.t.) 1 hour prior
to the injury (Fig. 1AC). Quite similar results were also
observed when LPA was applied 24 h prior to the observa-
tion (Fig. 1BD).
We have recently proposed that nociceptive fibers could
be pharmacologically classified into three types in terms
of neonatal capsaicin-sensitivity and spinal antagonism,
by use of APF test in mice[6]. This classification would
have an important advantage that nociceptive responses
through three different fibers were distinctly affected in
mice with partial sciatic nerve injury. There is a loss of
nociceptive responses through type-1 C-fibers, which are
sensitive to neonatal capsaicin, and use SP and NK1 recep-
tor as the spinal pain transmission. Although no change is
found in the nociceptive responses through type-2 C-fib-
ers, which are also sensitive to neonatal capsaicin, but useMolecular Pain 2006, 2:25 http://www.molecularpain.com/content/2/1/25
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glutamate and NMDA receptor, marked enhancement is
observed with the nociceptive responses through type-3
A-fibers, which are not sensitive to neonatal capsaicin, but
use glutamate and NMDA receptor. As shown in Table 1,
the nociceptive response induced by SP (i.pl.) through
type-1 C-fibers is the case, which showed a complete loss
of responses in mice with injury. Similar results were
observed with B2-type bradykinin receptor agonist and
nociceptin/orphanin FQ [18,21].
The major conclusion of the present study is that LPA1
receptor activation is also involved in this loss of function
through type-1C fibers in mice with nerve injury, which
causes neuropathic pain and underlying alterations of
gene expressions and demyelination. BoNT/C3 is a useful
pharmacological tool to block this LPA1-mediated
changes, since it shows a potent and long-lasting blockade
of RhoA pathway, a major downstream of signaling[16].
Another excellent tool is LPA1
-/- mice, which abolish the
nerve injury-induced thermal hyperalgesia and mechani-
cal allodynia[16]. In experiments using these two tools,
nerve injury-induced loss of SP (i.pl.)-mediated C-fiber
responses are mediated through RhoA activation through
LPA1 receptor. The use of pharmacological neuropathic
pain model following single i.t. injection of LPA also pro-
vide the important evidence for the validity of this conclu-
sion.
Such a loss of type-1 C-fiber responses would be explained
by the finding that spinal SP-immunoreactivity was mark-
edly reduced in mice with injury (Fig. 1A). The use of
BoNT/C3, LPA1
-/- mice and LPA (i.t.)-induced neuropathic
pain model revealed that down-regulation of SP-immu-
noreactivity in the dorsal horn is also mediated through
the activation of LPA1 receptor and RhoA. These observa-
tions are in a good contrast with the previous findings that
the nerve injury-induced activation of LPA1 receptor and
RhoA causes functional changes in myelinated A-fibers,
such as demyelination and up-regulation of Ca2+ channel
α2δ-1 subunit in medium/large neurons of DRG, both
which may underlie the molecular mechanisms for neuro-
pathic pain [16]. Regarding to the site of LPA action, we
have observed that LPA (i.pl.) caused nociception through
type-1 C-fiber [22,23], and demyelination of A-fibers
[16]. However, it remains which A-fibers or myelinating
Schwann cells are target underlying LPA-induced demyeli-
nation. The study using ex vivo culture experiments would
be the next subject.
The present study demonstrates that the loss of spinal SP
transmission via C-fibers is mediated through the activa-
tion of LPA1 receptor and RhoA, as seen in the case with
up-regulation of A-fibers.
Abbreviations
SP: substance P, LPA: Lysophoshatidic acid, BoNT/C3: C3-
typed botulinum toxin, APF: Algogenic-induced paw-
flexor response, i.t.: intrathecal, i.pl.: intraplantarly
Table 1: Loss of nerve injury- and LPA-induced spinal SP-mediated functional reduction in LPA1
-/- mice and mice with BoNT/C3 
treatment.
SP (0.01 pmol, i.pl.) SP (0.1 pmol, i.pl.) SP (1 pmol, i.pl.)
WT (Sham) 19.2 ± 2.4 36.0 ± 1.9 52.8 ± 2.4
WT (Injury) 5.7 ± 3.6 * 10.9 ± 3.9 * 8.6 ± 6.6 *
KO (Injury) 20.0 ± 4.5 # 34.9 ± 4.6 # 52.2 ± 2.1 #
Sham (Veh) 13.0 ± 2.3 23.8 ± 3.1 66.2 ± 6.6
Injury (Veh) 3.8 ± 0.5 * 6.1 ± 3.7 * 14.6 ± 7.7 *
Injury (BoNT/C3) 11.1 ± 6.8 # 21.2 ± 5.6 # 65.1 ± 8.8 #
WT (Veh) 10.1 ± 3.6 23.9 ± 4.6 53.2 ± 3.2
WT (LPA) 0 * 6.3 ± 0.8 * 11.1 ± 4.0 *
KO (LPA) 13.3 ± 2.6 # 28.2 ± 2.0 # 52.9 ± 1.7 #
Veh (Veh) 9.2 ± 1.2 21.6 ± 3.2 64.8 ± 6.0
LPA (Veh) 1.2 ± 0.2 * 4.8 ± 0.1 * 12.0 ± 4.8 *
LPA (BoNT/C3) 10.1 ± 1.9 # 19.2 ± 4.8 # 62.4 ± 6.0 #
Nociceptive flexor responses induced by injection (2 μl) of SP at each dose were normalized to the 'maximal reflex' defined as the biggest response 
among the responses occurring immediately after cannulation. Significance was set to *, #p < 0.05. Data are presented as means ± S.E.M. from 
experiments using at least 6 mice.
WT (Sham), WT (Injury) and KO (Injury) represent LPA1
+/+ mice with sham-operation, LPA1
+/+ mice with injury, and LPA1
-/- mice with injury, 
respectively.
Sham (Veh), Injury (Veh) and Injury (BoNT/C3) represent sham-operated mice with vehicle treatment, injured mice with vehicle treatment, and 
injured mice with BoNT/C3 (10 ng, 1 hr before injury), respectively.
WT (Veh), WT (LPA) and KO (LPA) represent LPA1
+/+ mice with vehicle-treatment, LPA1
+/+ mice with LPA-treatment injury, and LPA1
-/- mice with 
LPA-treatment, respectively.
Veh (Veh), LPA (Veh) and LPA (BoNT/C3) represent vehicle-treated mice with vehicle treatment, LPA-treated mice with vehicle treatment, and 
LPA-treated mice with BoNTC3 (10 ng, 1 hr before LPA treatment), respectively.Molecular Pain 2006, 2:25 http://www.molecularpain.com/content/2/1/25
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